News and Views
Nature Chemical Biology 2, 63 - 64 (2006)
doi:10.1038/nchembio0206-63
Inhibitors of Bcr-abl... breaking new ground again
Jeffrey F Ohren1 & Judith S Sebolt-Leopold1
- Jeffrey F. Ohren is in Chemical Technologies and Judith S. Leopold is in Mechanistic and Target Biology, Ann Arbor Laboratories, Pfizer Global Research and Development, Ann Arbor, Michigan 48105, USA. e-mail: Judith.Leopold@Pfizer.com.
Abstract
The report of a new class of potent and highly selective inhibitors of Bcr-abl highlights the potential for a truly leukemia-specific drug with no expected off-target activity. GNF-2, as a representative compound of this class, may have inspired the identification of a region of Bcr-abl that is amenable to drug design, just as imatinib did almost a decade ago.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Killing two kinase families with one stoneNature Chemical Biology News and Views (01 Nov 2008)
RESEARCH
Allosteric inhibitors of Bcr-abl?dependent cell proliferationNature Chemical Biology Article (01 Feb 2006)
Activation of tyrosine kinases by mutation of the gatekeeper threonineNature Structural & Molecular Biology Article (01 Oct 2008)
See all 5 matches for Research
